Latest1 information on COVID-19

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Not Recruiting

Trial ID: NCT01203358

Age - N/A-6 Hours Gender - All Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.

Official Title

Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome

Stanford Investigator(s)

David K. Stevenson, M.D.

Eligibility


Inclusion Criteria:

   - Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were
   receiving assisted ventilation with 30% oxygen or more

Exclusion Criteria:

   - Less than 6 hours of age

View More
View Less

Intervention(s):

drug: Exosurf

drug: Survanta

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2022 Stanford Medicine